Revenue Growth - Revenue for the year ended December 31, 2025, increased to RMB 220.05 million, representing a year-on-year growth of 79.91% from RMB 122.31 million in 2024[4] - Revenue for the year ended December 31, 2025, reached RMB 220,049,000, a significant increase from RMB 122,311,000 in 2024, representing an increase of 80%[15] - Revenue from the hospital-based integrated software solutions amounted to RMB 113,925,000, up from RMB 79,316,000 in the previous year, reflecting a growth of about 43%[26] - Revenue from the outpatient integrated software solutions increased to RMB 53,302,000 from RMB 26,789,000, marking a growth of approximately 99%[26] - New revenue from the sale of medical AI large language model solutions amounted to RMB 49.78 million[122] User Engagement - The number of patients using the system rose from approximately 1,800,000 times in 2024 to about 3,300,000 times by the end of 2025, indicating significant user engagement[6] - Average monthly active users increased by 99.14%, from 2,154.67 in 2024 to 4,290.75 in 2025, with December 2025 seeing 10,229 monthly active users, up 72.52% from 5,929 in December 2024[6] - Daily average usage time per user in 2025 was 23.29 minutes, reflecting strong user retention and compliance with interventions[122] Clinical Trials and Product Development - The clinical trial for the reading disorder rehabilitation software is progressing well, with 43 participants enrolled and expected to complete registration clinical research by the end of 2026[8] - The clinical trial for cognitive digital therapy in patients with cardiovascular diseases and cognitive impairment is nearing completion, with plans to submit registration documents in the second quarter of 2026[9] - The depression treatment software is set to enter the clinical trial phase in the second quarter of 2026, with commercialization expected by the end of 2028[10] - A breakthrough in ADHD treatment was achieved through a collaboration with Peking University Sixth Hospital, demonstrating significant improvement in core symptoms[11] - The digital therapy product for bone injury and pain has completed preclinical research, with plans to initiate registration clinical studies in the second quarter of 2026[12] Financial Performance - The company reported a net loss of RMB 316,364,000 for 2025, compared to a net loss of RMB 198,610,000 in 2024, reflecting a worsening financial position[15] - Gross profit for 2025 was RMB 89,454,000, compared to RMB 54,013,000 in 2024, indicating a gross margin improvement[15] - The company incurred total financial costs of RMB 23,986 thousand for the year ending December 31, 2025, compared to RMB 22,025 thousand in 2024[38] - The company reported a total loss of RMB 14,591 thousand in other expenses for the year ending December 31, 2025, compared to a gain of RMB 3,326 thousand in 2024[37] - The adjusted net loss (non-IFRS measure) for the year ended December 31, 2025, was RMB 239.15 million, compared to RMB 161.96 million in 2024[146] Research and Development - The company’s R&D expenses increased to RMB 165,904,000 in 2025 from RMB 119,424,000 in 2024, highlighting a focus on innovation[15] - The company has developed a cognitive training intervention system based on the BrainAuGPT model, aimed at providing personalized strategies for cognitive impairment patients[13] - The company has a strong R&D team of 128 professionals, with an average of over six years of experience in the digital therapy industry, focusing on unmet clinical needs and innovative technologies[98] Assets and Liabilities - The company’s non-current assets increased to RMB 71,431,000 in 2025 from RMB 51,363,000 in 2024, indicating growth in long-term investments[16] - The total assets less current liabilities improved to RMB 308,947,000 in 2025 from a negative RMB 182,512,000 in 2024, showing a positive shift in financial health[16] - Trade receivables increased to RMB 143,491,000 in 2025 from RMB 105,312,000 in 2024, reflecting a growth of 36.2%[57] - Cash and cash equivalents decreased to RMB 430,358,000 in 2025 from RMB 343,882,000 in 2024, showing a decline of 25.2%[61] - The company has bank borrowings of RMB 339,060,000 as of December 31, 2025, significantly up from RMB 14,072,000 in 2024[70] Governance and Compliance - The company’s financial statements are prepared in accordance with International Financial Reporting Standards, ensuring compliance with relevant regulations[20] - The audit committee has reviewed the annual financial performance for the year ending December 31, 2025, and found no discrepancies in the accounting policies adopted by the company[158] - The company has not engaged in any significant litigation or arbitration that could adversely affect its financial condition or operating results during the reporting period[153] Market Strategy and Expansion - The company is focused on providing digital therapy integrated software solutions for cognitive impairment in China, indicating a strategic emphasis on this market segment[19] - The company is actively expanding its digital therapy offerings internationally, particularly targeting Southeast Asia, to address the global shortage of cognitive health resources[108] - The company aims to expand its product line to cover new indications for cognitive impairment, although success is not guaranteed[87] Employee Costs and Compensation - Total employee costs for 2025 amounted to RMB 171,793,000, an increase from RMB 144,923,000 in 2024, which is an increase of approximately 18%[44] - The total remuneration for executive directors was RMB 69,623,000 for the year ending December 31, 2025, compared to RMB 46,939,000 in 2024, reflecting an increase of approximately 48%[45] - The total compensation for the five highest-paid employees in the group for the year ending December 31, 2025, is RMB 4,439,000, a decrease of 72.9% from RMB 16,376,000 in 2024[48] Shareholder Information - The company did not declare or pay any dividends for the year ending December 31, 2025, consistent with 2024[49] - The company completed a placement of 92,000,000 shares at HKD 5.6 per share, raising approximately HKD 500.68 million, with specific intended uses for the proceeds detailed in subsequent announcements[160] - The company will suspend share transfer registration from June 15 to June 18, 2026, to determine eligible shareholders for the annual general meeting on June 18, 2026[162]
脑动极光(06681) - 2025 - 年度业绩